Jacek Otlewski
University of Wrocław
Binding siteBiophysicsMutantMolecular biologyCytotoxic T cellReceptorEnzymeChemistryPhage displayTrypsin inhibitorChymotrypsinTrypsinProtein structureBiochemistryStereochemistryFibroblast growth factorCrystallographyFibroblast growth factor receptorBiologyCell biologyCancer cell
153Publications
44H-index
4,499Citations
Publications 154
Newest
#1Isabella Damiani (University of Milan)H-Index: 1
#2Silvia Castiglioni (University of Milan)H-Index: 8
Last. Stefano Bellosta (University of Milan)H-Index: 37
view all 9 authors...
A promising approach for the development of high-affinity tumor targeting ADCs is the use of engineered protein drugs, such as affibody molecules, which represent a valuable alternative to monoclonal antibodies (mAbs) in cancer-targeted therapy. We developed a method for a more efficient purification of the ZHER2:2891DCS affibody conjugated with the cytotoxic antimitotic agent auristatin E (MMAE), and its efficacy was tested in vitro on cell viability, proliferation, migration, and apoptosis. Th...
Source
#1Marta Poźniak (UWr: University of Wrocław)
#2Weronika Zarzycka (UWr: University of Wrocław)
Last. Łukasz Opaliński (UWr: University of Wrocław)H-Index: 7
view all 8 authors...
FGFRs are cell surface receptors that, when activated by specific FGFs ligands, transmit signals through the plasma membrane, regulating key cellular processes such as differentiation, division, motility, metabolism and death. We have recently shown that the modulation of the spatial distribution of FGFR1 at the cell surface constitutes an additional mechanism for fine-tuning cellular signaling. Depending on the multivalent, engineered ligand used, the clustering of FGFR1 into diverse supramolec...
Source
#1Marta Poźniak (UWr: University of Wrocław)
#2Natalia Porębska (UWr: University of Wrocław)H-Index: 3
Last. Łukasz Opaliński (UWr: University of Wrocław)H-Index: 7
view all 10 authors...
BACKGROUND Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific for tumor-associated antigens enables sparing the healthy cells and thereby reduces unwanted side effects. Overexpression of fibroblast growth factor receptor 1 (FGFR1) has been demonstrated in numerous tumors and thereby constitutes a convenient molecular target for selective cancer trea...
1 CitationsSource
Receptor tyrosine kinases (RTKs) constitute a large group of cell surface proteins that mediate communication of cells with extracellular environment. RTKs recognize external signals and transfer information to the cell interior, modulating key cellular activities, like metabolism, proliferation, motility, or death. To ensure balanced stream of signals the activity of RTKs is tightly regulated by numerous mechanisms, including receptor expression and degradation, ligand specificity and availabil...
1 CitationsSource
#1Natalia Porębska (UWr: University of Wrocław)H-Index: 3
#2Marta Pozniak (UWr: University of Wrocław)H-Index: 1
Last. Lukasz Opalinski (UWr: University of Wrocław)H-Index: 3
view all 10 authors...
Abstract Fibroblast growth factor receptors (FGFRs) are integral membrane proteins involved in various biological processes including proliferation, migration and apoptosis. There are a number of regulatory mechanisms of FGFR signaling, which tightly control the specificity and duration of transmitted signals. The effect of the FGFRs spatial distribution in the plasma membrane on receptor-dependent functions is still largely unknown. We have demonstrated that oligomerization of FGF1 with coiled-...
1 CitationsSource
#1Katarzyna Dominika Sluzalska (UWr: University of Wrocław)H-Index: 1
#2Jakub Sławski (UWr: University of Wrocław)H-Index: 3
Last. Malgorzata Zakrzewska (UWr: University of Wrocław)H-Index: 17
view all 6 authors...
Abstract Fibroblast growth factors 1 and2 (FGF1 and FGF2) are mainly considered as ligands of surface receptors through which they regulate a broad spectrum of biological processes. They are secreted in non-canonical way and, unlike other growth factors, they are able to translocate from the endosome to the cell interior. These unique features, as well as the role of the intracellular pool of FGF1 and FGF2, are far from being fully understood. An increasing number of reports address this problem...
2 CitationsSource
Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective therapeutics, the protein bioconjugates, composed of targeting proteins (antibodies or receptor ligands) connected to highly cytotoxic drugs by a specific linker. Due to very high affinity and selectivity of targeting proteins the bioconjugates recognize ...
Source
#1Karolina Jendryczko (UWr: University of Wrocław)
#2Julia Chudzian (UWr: University of Wrocław)H-Index: 2
Last. Anna Szlachcic (UWr: University of Wrocław)H-Index: 10
view all 8 authors...
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptide based on FGF2 sequence was used to construct a FGFR1-targeting peptibody. We have shown that this peptide ensures specific delivery of peptibodyF2 into FGFR1-expressing cells. In order to use peptib...
Source
#1Marta Pozniak (UWr: University of Wrocław)H-Index: 1
#2Aleksandra Sokolowska-Wedzina (UWr: University of Wrocław)H-Index: 7
Last. Lukasz Opalinski (UWr: University of Wrocław)H-Index: 3
view all 10 authors...
Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism and death. Overexpression of FGFR1 is observed in numerous tumors and thus constitutes an attractive molecular target for selective cancer treatment. Targeted anti-cancer therapies aim for the precise delivery of drugs into cancer cells, sparing the healthy ones and thus limiting unwanted side effects. One of the key steps in target...
3 CitationsSource
In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an unfulfilled n...
3 CitationsSource